Department of Obsterics and Gynecology, Shengjing Hospital, China Medical University, Shenyang 110004, PR China.
Oncol Rep. 2012 Jun;27(6):1801-6. doi: 10.3892/or.2012.1708. Epub 2012 Mar 7.
The aim of this study was to investigate the detection rate and methods of micrometastases in early-stage cervical cancer by detecting the expression of high-risk HPV DNA and CK19 in pelvic lymph nodes. A total of 104 lymph nodes with/without pathologically confirmed metastases, from 28 patients with early-stage cervical cancer, were included for detection of high-risk HPV DNA and CK19 expression using in situ hybridization and immunohistochemistry, respectively. The detection rate of high-risk HPV DNA and CK19 in lymph nodes in patients with pathologically-confirmed lymph node metastases was higher compared to that in lymph nodes in patients without pathologically-confirmed lymph node metastases (P<0.001). In all 80 pathologically-negative lymph nodes, the positivity rates of high-risk HPV DNA and CK19 detection were 45 and 25%, respectively. In 57 lymph nodes in patients without pathologically-confirmed lymph node metastases the positivity rates of high-risk HPV DNA and CK19 detection were 43.5 and 24.6%. The detection rate of high-risk HPV DNA and CDK19 in 15 patients without pathologically-confirmed lymph node metastases were 60 and 46.6%, respectively. The detection rates of high-risk HPV DNA and CK19 in 104 lymph nodes were 56.7 and 41.3% (KI=0.46). The results of the two detection methods showed good consistency. Both detection of high-risk HPV DNA by in situ hybridization, and CK19 by immunohistochemical method detected lymph node micrometastases in early-stage cervical cancer. As a method of detection on the molecular level, in situ hybridization was more sensitive for the detection of lymph node micrometastases in early-stage cervical cancer.
本研究旨在通过检测盆腔淋巴结中高危型 HPV DNA 和 CK19 的表达，来探讨早期宫颈癌微转移的检测率和方法。共纳入 28 例早期宫颈癌患者的 104 枚有/无病理证实转移的淋巴结，分别采用原位杂交和免疫组化法检测高危型 HPV DNA 和 CK19 的表达。与无病理证实的淋巴结转移患者相比，有病理证实的淋巴结转移患者的淋巴结中高危型 HPV DNA 和 CK19 的检测率更高（P<0.001）。在所有 80 例病理阴性的淋巴结中，高危型 HPV DNA 和 CK19 检测的阳性率分别为 45%和 25%。在 57 例无病理证实的淋巴结转移患者中，高危型 HPV DNA 和 CK19 检测的阳性率分别为 43.5%和 24.6%。在 15 例无病理证实的淋巴结转移患者中，高危型 HPV DNA 和 CDK19 的检测率分别为 60%和 46.6%。104 枚淋巴结中高危型 HPV DNA 和 CK19 的检测率分别为 56.7%和 41.3%（KI=0.46）。两种检测方法的结果具有良好的一致性。原位杂交法检测高危型 HPV DNA 和免疫组化法检测 CK19 均可检测早期宫颈癌的淋巴结微转移。作为一种分子水平的检测方法，原位杂交法对早期宫颈癌淋巴结微转移的检测更为敏感。
